Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Arxxant "approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Lilly believes it may have to conduct an additional trial of Arxxant (ruboxistaurin) following receipt of an Aug. 17 "approvable" letter. The firm said it plans to meet with FDA to determine whether the agency's request for additional data could be supported by data from an ongoing trial. In July, Lilly announced a co-promotion deal for Arxxant with Alcon (1Pharmaceutical Approvals Monthly August 2006, p. 2)...
Advertisement

Related Content

FDA requests additional Arxxant trial
Lilly and Alcon to co-promote Arxxant

Topics

Advertisement
UsernamePublicRestriction

Register

PS003402

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel